Byondis B.V.
Records under this name other than the patents Byondis B.V. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 25 patents it holds.
Showing 1 to 9 of 9 · Back to Byondis B.V.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,092,659 | Duocarmycin Adcs for Use in Treatment of Endometrial Cancer Lapsed on the fee record Ended Oct 9, 2026 · High confidence | Lapsed on the fee record | Ended Oct 9, 2026 | High confidence |
| US 11,382,982 | Duocarmycin Adcs Showing Improved in Vivo Antitumor Activity Lapsed on the fee record Ended Jul 12, 2026 · High confidence | Lapsed on the fee record | Ended Jul 12, 2026 | High confidence |
| US 11,008,400 | Anti-5T4 antibodies and antibody-drug conjugates Lapsed on the fee record Ended May 18, 2025 · From the USPTO record | Lapsed on the fee record | Ended May 18, 2025 | From the USPTO record |
| US 9,629,924 | Conjugates of CC-1065 analogs and bifunctional linkers Lapsed on the fee record Ended Apr 25, 2025 · From the USPTO record | Lapsed on the fee record | Ended Apr 25, 2025 | From the USPTO record |
| US 9,580,501 | Anti-TNF alpha monoclonal secretory IgA antibodies and methods for treating inflammatory diseases Lapsed on the fee record Ended Feb 28, 2025 · From the USPTO record | Lapsed on the fee record | Ended Feb 28, 2025 | From the USPTO record |
| US 9,573,996 | Monoclonal antibodies to human proinflammatory cytokines and methods for treating inflammatory diseases Lapsed on the fee record Ended Feb 21, 2025 · From the USPTO record | Lapsed on the fee record | Ended Feb 21, 2025 | From the USPTO record |
| US 10,821,191 | SYD985 treatment of T-DM1 refractory cancer patients Lapsed on the fee record Ended Nov 3, 2024 · From the USPTO record | Lapsed on the fee record | Ended Nov 3, 2024 | From the USPTO record |
| US 8,158,590 | Triazole-containing releasable linkers, conjugates thereof, and methods of preparation Lapsed on the fee record Ended Apr 17, 2024 · From the USPTO record | Lapsed on the fee record | Ended Apr 17, 2024 | From the USPTO record |
| US 7,223,837 | Elongated and multiple spacers in activatible prodrugs Term ended Term ended Mar 25, 2022 · From the USPTO record | Term ended | Term ended Mar 25, 2022 | From the USPTO record |